The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2017

Filed:

Dec. 23, 2011
Applicants:

Rafael Yuste, New York, NY (US);

Roberto Etchenique, Buenos Aires, AR;

Luis Baraldo, Buenos Aires, AR;

Inventors:

Rafael Yuste, New York, NY (US);

Roberto Etchenique, Buenos Aires, AR;

Luis Baraldo, Buenos Aires, AR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07F 15/00 (2006.01); A61K 31/555 (2006.01); A61K 41/00 (2006.01); A61K 31/4045 (2006.01); A61K 31/41 (2006.01); A61K 31/4409 (2006.01); A61K 31/465 (2006.01); A61K 31/198 (2006.01); A61K 31/675 (2006.01); A61K 47/48 (2006.01); A61N 5/06 (2006.01); B01J 19/12 (2006.01); A61N 5/067 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0042 (2013.01); A61K 31/198 (2013.01); A61K 31/4045 (2013.01); A61K 31/41 (2013.01); A61K 31/4409 (2013.01); A61K 31/465 (2013.01); A61K 31/675 (2013.01); A61K 47/48076 (2013.01); A61N 5/062 (2013.01); B01J 19/12 (2013.01); C07F 15/0053 (2013.01); A61N 2005/067 (2013.01); A61N 2005/0657 (2013.01); A61N 2005/0659 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0662 (2013.01); B01J 2219/12 (2013.01);
Abstract

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.


Find Patent Forward Citations

Loading…